Vectura
A provider of innovative inhaled drug delivery services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | N/A | £150m | Acquisition |
| Total Funding | 000k | ||
| GBP | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 191 % | (12 %) | 8 % | 11 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 26 % | 28 % | 16 % | 21 % | 22 % | 29 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | (25 %) | (58 %) | (55 %) | (12 %) | 64 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Vectura is a leading pharmaceutical company specializing in the development of inhaled medicines. The company leverages its extensive experience in formulation science, device technology, and regulatory support to help its partners bring dry powder inhalers (DPI), pressurized metered-dose inhalers (pMDI), and nebulizer medicines to market. Vectura operates in the pharmaceutical and healthcare market, serving clients ranging from large pharmaceutical companies to smaller biotech firms. The business model is based on providing comprehensive development services, including pharmaceutical analysis, process development, technical transfer, and product manufacturing. Vectura generates revenue through service fees, licensing agreements, and royalties from the sales of inhaled medicines developed in collaboration with its partners. The company has a proven track record, with 13 inhaled medicines successfully launched, generating $11 billion in sales and benefiting 10 million patients worldwide in 2020.
Keywords: inhaled medicines, formulation science, device technology, regulatory support, DPI, pMDI, nebulizer, pharmaceutical development, biotech, licensing agreements.
